Related references
Note: Only part of the references are listed.Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer
Lisha Xiang et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines
Mario Campone et al.
BREAST JOURNAL (2013)
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer
G. Bisagni et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Progression of genotype-specific oral cancer leads to senescence of cancer-associated fibroblasts and is mediated by oxidative stress and TGF-β
Yazan Hassona et al.
CARCINOGENESIS (2013)
Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer
Nabil Ismaili et al.
PRESSE MEDICALE (2013)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Contemporary issues and the potential uses of capecitabine in metastatic breast cancer
Peter Barrett-Lee et al.
CANCER TREATMENT REVIEWS (2009)
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer
Laure Favier et al.
BREAST (2008)
A phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes
Laura G. Estevez et al.
CLINICAL BREAST CANCER (2008)
Capecitabine and vinorelbine as first-line treatment in elderly patients (>= 65 years) with metastatic breast cancer - A phase II trial (SAKK 25/99)
D. Hess et al.
ONCOLOGY (2007)
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
R. Leonard et al.
ANNALS OF ONCOLOGY (2006)
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
C Pacilio et al.
BRITISH JOURNAL OF CANCER (2006)
Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy
M Mano
CANCER TREATMENT REVIEWS (2006)
Capecitabine/vinorelbine:: An effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer
Franco Nole et al.
CLINICAL BREAST CANCER (2006)
Capecitabine plus docetaxel combination therapy -: Cost-effectiveness in patients with anthracycline-pretreated advanced breast carcinoma
S Verma et al.
CANCER (2005)
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer
A Welt et al.
ANNALS OF ONCOLOGY (2005)
Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane
JH Ahn et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2004)
Evidence-based use of neoaduvant taxane in operable and inoperable breast cancer
LG Estévez et al.
CLINICAL CANCER RESEARCH (2004)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
J O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
